Moreover, a biomimetic nanovaccine co-delivering IL-15 and tumor-associated antigens selectively targets IL-15 to antigen-specific CTLs, reducing off-target toxicity and extending the cytokine's half-life by 8.2-fold. This evidence concerns the gene IL15 and neoplasm.